GeNeuro to Present at 3rd 2019 HERVs & Disease International Workshop on Human Endogenous Retroviruses (HERVs) and Diseases

- A must-attend and rapidly growing event with experts around the world: 36 speakers from 10 countries
- In-depth scientific review of the role played by the HERVs in a broad range of diseases including multiple sclerosis, amyotrophic lateral sclerosis and cancer
- Focus on positive Phase 2 clinical trial results with GeNeuro’s temelimab through presentation by PD Dr. David Kremer, Heinrich-Heine-University of Düsseldorf, Germany

Geneva, Switzerland, October 31, 2019 – 7:30 am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes, announced that the company will present at and sponsor the 3rd HERVs & Disease International Workshop on Human Endogenous Retroviruses and Diseases, to be held November 5-6, 2019, in Lyon, France.

This rapidly growing conference brings together experts from around the world to discuss human endogenous retroviruses (HERVs) and the role they play in a broad range of diseases, including multiple sclerosis, amyotrophic lateral sclerosis, psoriasis, Type 1 diabetes and cancer. HERVs are known to have originated from retroviral infections of germline cells, resulting in retrovirus DNA insertions (termed proviruses), which have been passed to the genomes of modern humans during evolution. A rapid expansion of knowledge in the HERV field has resulted in a significant increase in the attendance at the event. After the first congress in 2015 held in Lyon-France and the second in 2017 held in Washington DC, USA, this year, back to Lyon, the event will gather 36 speakers from 10 countries from Europe, Northern and Southern America, Middle East and Australia. (https://www.hervanddisease.com)

With this expanding knowledge, there is a new understanding of the diversity of the genetic distribution of HERV families, as well as on the factors leading to their expression. CNS diseases, where the evidence on the pathogenic role of specific HERVs has become extremely strong, remain a key area of research. For example, there is growing evidence that pathogenic envelope protein from HERV-W family, pHERV-W Env, plays a causal role in the development of MS, which is supported by positive Phase 2 clinical trial results with GeNeuro’s lead drug candidate temelimab. Research also suggests that HERVs play a key role in the onset and development of diseases, such as oncology, amyotrophic lateral sclerosis (ALS), psychoses and inflammatory myopathies.

Hervé Perron, Chief Scientific Officer of GeNeuro and member of the conference organizing committee, said: “GeNeuro is the leader in developing a new approach to the treatment of diseases associated with HERV expression; and, as such, we are very proud to take part in and sponsor this prestigious conference. The HERV and Disease meeting provides experts in the field a unique opportunity to share and discuss their knowledge and we are looking forward to the opportunity to engage with this community. The presentations this year are broad and diverse, illustrating the continued expansion of the field.”

GeNeuro Presentations:

November 5, 2019

2:45 pm Biochemical characterization of oligomeric antigens from HERV glycoproteins
Benjamin Charvet

November 6, 2019

9:30 am Preclinical study of HERV-W involvement in Type 1 diabetes
Sandrine Levet
About GeNeuro

GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 24 employees and rights to 17 patent families protecting its technology.

For more information, visit: www.geneuro.com

Contacts:

<table>
<thead>
<tr>
<th>GeNeuro</th>
<th>NewCap (France)</th>
<th>Halsin Partners</th>
<th>LifeSci Advisors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jesús Martin-Garcia</td>
<td>Investor Relations –</td>
<td>Media Relations –</td>
<td>Investor Relations –</td>
</tr>
<tr>
<td>Chairman and CEO</td>
<td>Mathilde Bohin / Louis-</td>
<td>Mike Sinclair</td>
<td>Chris Maggos</td>
</tr>
<tr>
<td></td>
<td>Victor Delouvrier</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+33 1 44 71 98 52</td>
<td>+33 1 44 71 94 98</td>
<td>+44 20 7318 2955</td>
<td>+41 79 367 6254</td>
</tr>
<tr>
<td></td>
<td>Media Relations – Arthur Rouillé</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+41 22 552 48 00</td>
<td>+33 1 44 71 94 98</td>
<td>+44 20 7318 2955</td>
<td>+41 79 367 6254</td>
</tr>
<tr>
<td><a href="mailto:investors@geneuro.com">investors@geneuro.com</a></td>
<td><a href="mailto:geneuro@newcap.eu">geneuro@newcap.eu</a></td>
<td><a href="mailto:msinclair@halsin.com">msinclair@halsin.com</a></td>
<td><a href="mailto:chris@lifesciadvisors.com">chris@lifesciadvisors.com</a></td>
</tr>
</tbody>
</table>

Disclaimer

This press release contains certain forward-looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.